NSE: SUNPHARMA · 22 October 2026
- SUN PHARMACEUTICAL IND L (SUNPHARMA) shares traded higher during the session, gaining 0.74% to settle at ₹1,758.00 after moving between an intraday low of ₹1,719.10 and a high of ₹1,758.00.
- Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was supported by pivotal registration study data demonstrating a 55% objective response rate with durable responses and a low incidence of high-grade immune-mediated adverse reactions. This designation follows its prior assignment in metastatic cutaneous squamous cell carcinoma.
- Trading volume was 1.18 times the 20-day average daily volume.
Why is Sun Pharmaceutical Ind L share price rising on 22 October 2026?
SUN PHARMACEUTICAL IND L (SUNPHARMA) shares traded higher during the session, gaining 0.74% to settle at ₹1,758.00 after moving between an intraday low of ₹1,719.10 and a high of ₹1,758.00.
The broader market experienced a notable pullback as the Nifty index fell 0.88%, whereas the Nifty Pharma sector benchmark remained relatively resilient, edging down by just 0.07%. Sun Pharma's positive session performance helped it outperform both the broader market barometer and its immediate sectoral peer group on the day, building on a modest 0.66% gain over the preceding 5 trading days despite a 4.79% decline over the trailing 20 trading days.
While the stock demonstrated resilience against broader market weakness, company-specific updates include recent credit rating affirmations from CRISIL and ICRA citing a strong business and financial profile, alongside a recent press release highlighting the elevation of UNLOXCYT to a Category 2A preferred designation in NCCN guidelines for locally advanced cutaneous squamous cell carcinoma. However, these announcements served as background context rather than direct immediate triggers for today's price action.
17.79 lakh shares traded by 22 October 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 15.10 lakh shares (1.18 times). The five-day average daily volume was 15.71 lakh shares. Separately, the NSE report for 22 October 2026 showed 11.72 lakh shares delivered, representing 65.92% of that day’s traded volume. The same report recorded 72,383 trades.
The move appears consistent with stock-specific relative strength and steady institutional delivery participation (65.92% delivery rate) on a day when broader equity benchmarks traded notably lower. No single same-day operational event or announcement was explicitly linked to the session's gains.
Latest Company Developments
Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was supported by pivotal registration study data demonstrating a 55% objective response rate with durable responses and a low incidence of high-grade immune-mediated adverse reactions. This designation follows its prior assignment in metastatic cutaneous squamous cell carcinoma.
Enhances the clinical positioning and commercial adoption potential of Sun Pharma's innovative oncology portfolio in regulated markets.
CRISIL Ratings and ICRA Limited assigned 'Crisil AAA/Stable' and '[ICRA]AAA (Stable)' ratings respectively to the company's proposed non-convertible debenture programme of up to INR 10,000 crore while reaffirming existing credit facilities and commercial paper ratings. The rating rationale factors in the company's leadership in domestic formulations, robust specialty products portfolio, and financial profile considerations surrounding the proposed acquisition of Organon & Co.
Reflects high creditworthiness and institutional confidence in the company's financial structure and debt-servicing capability.
The board of directors took note of the resignation of Mr. Gautam Doshi as a Non-Executive Independent Director effective 12 October 2026, citing personal commitments with no other material reasons stated. Simultaneously, the board approved the issuance of listed, rated, unsecured, redeemable non-convertible debentures on a private placement basis up to INR 10,000 crore.
Represents a board-level governance transition alongside capital-raising authorizations for upcoming strategic initiatives.
'Completion and Result of Postal Ballot dated 25 August 2026'.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.01% on 30 September 2026. This compares with 12.84% on 30 June 2026, a change of +0.17 percentage points.
The filing reported 51 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Upcoming financial results and commentary for the quarter and half year ended 30 September 2026 scheduled for 30 October 2026.
- Progress and regulatory approvals regarding the proposed acquisition of Organon & Co.
- Commercial uptake and adoption of newly launched specialty products including UNLOXCYT and Leqselvi in regulated markets.
- Sustained delivery volume trends and performance relative to the Nifty Pharma sector benchmark.
Other Dated Coverage
- Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Falling 0.17% | 21 October 2026 — 21 October 2026
- Sun Pharma in Focus After CRISIL and ICRA Assign NCD Ratings | 15 October 2026 — 15 October 2026
- Sun Pharma in Focus After NCD Issuance Approval and Director Resignation | 14 October 2026 — 14 October 2026
More Sun Pharmaceutical Ind L news and dated analysis →
Frequently Asked Questions
What is the latest Sun Pharmaceutical Ind L company news?
Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The submission was supported by pivotal registration study data demonstrating a 55% objective response rate with durable responses and a low incidence of high-grade immune-mediated adverse reactions. This designation follows its prior assignment in metastatic cutaneous squamous cell carcinoma.
How strong was Sun Pharmaceutical Ind L’s trading volume?
17.79 lakh shares traded, 1.18 times the 20-day average daily volume. The price and volume data are dated 22 October 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.